Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer

Docetaxel (DTX) chemotherapy remains a standard-of-care for metastatic castration-resistant prostate cancer (CRPC). DTX modestly increases survival, yet results in frequent occurrence of side-effects and resistant disease. An alternate chemotherapy with greater efficacy and minimal side-effects is n...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Babcook, Melissa A., Shukla, Sanjeev, Fu, Pingfu, Vazquez, Edwin J., Puchowicz, Michelle A., Molter, Joseph P., Oak, Christine Z., MacLennan, Gregory T., Flask, Chris A., Lindner, Daniel J., Parker, Yvonne, Daneshgari, Firouz, Gupta, Sanjay
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4185215/
https://ncbi.nlm.nih.gov/pubmed/25122066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0451
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares